



(51) International Patent Classification:
A61B 18/04 (2006.01)

(21) International Application Number:
PCT/US2009/059609

(22) International Filing Date:
6 October 2009 (06.10.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/102,885 6 October 2008 (06.10.2008) US

(72) Inventor; and

(71) Applicant : SHARMA, Virender, K. [US/US]; 6531 N.
60th St., Paradise Valley, AZ 85253 (US).

(74) Agent: HAZIM, Ansari; Patentmetrix, 14252 Culver Dr.,
BOX 914, Irvine, CA 92604 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: METHOD AND APPARATUS FOR TISSUE ABLATION




FIG. 2D

(57) Abstract: The present invention is directed toward a device that performs ablation of tissue. The device has a catheter with a shaft through which an ablative agent can travel, a first positioning element attached to the catheter shaft at a first position and a second positioning element attached to the catheter shaft at a second position. The shaft also has ports through which the ablative agent can be released.



-
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

METHOD AND APPARATUS FOR TISSUE ABLATION

Field of the invention

The present invention relates to medical apparatus and procedures. More particularly, the present invention relates to a device for ablation of tissue in a hollow organ comprising a centering or positioning attachment in order to position the device at a consistent distance from the tissue to be ablated.

Background of the invention

Colon polyps affect almost 25% of the population over the age of 50. While most polyps are detected on colonoscopy and easily removed using a snare, flat sessile polyps are hard to remove using the snare technique and carry a high risk of complications, such as bleeding and perforation. Recently, with improvement in imaging techniques, more flat polyps are being detected. Endoscopically unresectable polyps require surgical removal. Most colon cancer arises from colon polyps and, safe and complete resection of these polyps is imperative for the prevention of colon cancer.

Barrett esophagus is a precancerous condition effecting 10-14% of US population with gastro esophageal reflux disease (GERD) and is the proven precursor lesion of esophageal adenocarcinoma, the fastest rising cancer in the developed nations. The incidence of the cancer has risen over 6 fold in the last 2 decades and mortality has risen by 7 fold. The 5-year mortality from esophageal cancer is 85%. Ablation of Barrett epithelium has shown to prevent its progression to esophageal cancer.

Dysfunctional uterine bleeding (DUB), or menorrhagia, affects 30% of women in reproductive age. These symptoms have considerable impact on a woman's health and quality of life. The condition is typically treated with endometrial ablation or a hysterectomy. The rates of surgical intervention in these women are high. Almost 30% of women in US will undergo hysterectomy by the age 60, with menorrhagia or DUB being the cause for surgery in 50-70% of these women. Endometrial ablation techniques have been FDA approved for women with abnormal uterine bleeding and with intramural fibroids less than 2 cm. The presence of submucosal uterine fibroids

1 and a large uterus size have been shown to decrease the efficacy of standard
2 endometrial ablation. Of the five FDA approved global ablation devices (namely,
3 Thermachoice, hydrothermal ablation, Novasure, Her Option, and microwave
4 ablation) only microwave ablation (MEA) has been approved for use where the
5 submucosal fibroids are less than 3 cm and are not occluding the endometrial cavity
6 and, additionally, for large uteri up to 14cm.

7 The known ablation treatments for Barrett esophagus include laser treatment
8 (Ertan et al, Am. J. Gastro., 90:2201-2203 [1995]), ultrasonic ablation (Bremner et al,
9 Gastro. Endo., 43:6 [1996]), photodynamic therapy (PDT) using photo-sensitizer
10 drugs (Overholt et al, Semin. Surq. Oncol., 1 :372-376 (1995), multipolar
11 electrocoagulation such as by use of a bicap probe (Sampliner et al.), Argon Plasma
12 Coagulation (APC;), Radiofrequency ablation (Sharma et al. Gastrointest Endosc)
13 and cryoablation (Johnston et al. Gastrointest Endosc). The treatments are delivered
14 with the aid of an endoscope and devices passed through the channel of endoscope or
15 alongside the endoscope.

16 Conventional techniques have inherent limitations, however, and have not
17 found widespread clinical applications. First, most of the hand held ablation devices
18 (Bicap probe, APC, cryoablation) are point and shoot devices that create small foci of
19 ablation. This ablation mechanism is operator dependent, cumbersome and time
20 consuming. Second, because the target tissue is moving due to patient movement,
21 respiration movement, normal peristalsis and vascular pulsations, the depth of
22 ablation of the target tissue is inconsistent and results in a non-uniform ablation.
23 Superficial ablation results in incomplete ablation with residual neoplastic tissue left
24 behind. Deeper ablation results in complications such as bleeding, stricture formation
25 and perforation. All of these limitations and complications have been reported with
26 conventional devices.

27 For example, radiofrequency ablation uses a rigid bipolar balloon based
28 electrode and radiofrequency thermal energy. The thermal energy is delivered by
29 direct contact of the electrode with the diseased Barrett epithelium allowing for a
30 relatively uniform, large area ablation. However, the rigid electrode does not
31 accommodate for variations in esophageal size and is ineffective in ablating tortuous
32 esophagus, proximal esophageal lesions as an esophagus narrows towards the top, and
33 esophagus at the gastroesophageal junction due to changes in the esophagus diameter.
34 Nodular disease in Barrett esophagus also cannot be treated using the rigid bipolar RF

1 electrode. Due to its size and rigidity, the electrode cannot be passed through the
2 scope. In addition sticking of sloughed tissue to the electrode impedes with delivery
3 of radiofrequency energy resulting in incomplete ablation. The electrode size is
4 limited to 3 cm, thus requiring repeat applications to treat larger lengths of Barrett
5 esophagus.

6 Photodynamic therapy (PDT) is a two part procedure that involves injecting a
7 photo-sensitizer that is absorbed and retained by the neoplastic and pre-neoplastic
8 tissue. The tissue is then exposed to a selected wavelength of light which activates the
9 photo-sensitizer and results in tissue destruction. PDT is associated with
10 complications such as stricture formation and photo-sensitivity which has limited its
11 use to the most-advanced stages of the disease. In addition, patchy uptake of the
12 photosensitizer results in incomplete ablation and residual neoplastic tissue.

13 Cryoablation of the esophageal tissues via direct contact with a liquid nitrogen
14 has been studied in both animal models and humans (Rodgers et al, Cryobiology,
15 22:86-92 (1985); Rodgers et al, Ann. Thorac. Surg. 55:52-7 [1983]) and has been
16 used to treat Barrett esophagus and (Johnston et al. Gastrointest Endosc) early
17 esophageal cancer (Grana et al, Int. Surg., 66:295 [1981]). A spray catheter that
18 directly sprays liquid N₂ or CO₂ (cryoablation) or argon (APC) to ablate Barrett tissue
19 in the esophagus has been described. These techniques suffer the shortcoming of the
20 traditional hand-held devices. Treatment using this probe is cumbersome and requires
21 operator control under direct endoscopic visualization. Continuous movement in the
22 esophagus due to respiration or cardiac or aortic pulsations or movement causes an
23 uneven distribution of the ablative agent and results in non-uniform and/or incomplete
24 ablation. Close or direct contact of the catheter to the surface epithelium may cause
25 deeper tissue injury, resulting in perforation, bleeding or stricture formation. Too
26 distant a placement of the catheter due to esophageal movement will result in
27 incomplete Barrett ablation, requiring multiple treatment sessions or buried lesions
28 with a continued risk of esophageal cancer. Expansion of cryogenic gas in the
29 esophagus results in uncontrolled retching which may result in esophageal tear or
30 perforation requiring continued suctioning of cryogen.

31 Colon polyps are usually resected using snare resection with or without the use
32 of monopolar cautery. Flat polyps or residual polyps after snare resection have been
33 treated with argon plasma coagulation or laser treatment. Both these treatments, have
34 the previously mentioned limitations. Hence, most large flat polyps undergo surgical

1 resection due to high risk of bleeding, perforation and residual disease using
2 traditional endoscopic resection or ablation techniques.

3 Most of the conventional balloon catheters traditionally used for tissue
4 ablation either heat or cool the balloon itself or a heating element such as a radio
5 frequency (RF) coils mounted on the balloon. This requires direct contact of the
6 balloon catheter with the ablated surface. When the balloon catheter is deflated, the
7 epithelium sticks to the catheter and sloughs off, thereby causing bleeding. Blood can
8 interfere with delivery of energy i.e. energy sink. In addition reapplication of energy
9 will result in deeper burn in the area where superficial lining has sloughed. Further,
10 balloon catheters cannot be employed for treatment in non cylindrical organs, like the
11 uterus or sinuses, and also do not provide non-circumferential or focal ablation in a
12 hollow organ. Additionally, if used with cryogenics as ablative agents, which expand
13 exponentially upon being heated, balloon catheters may result in a closed cavity and
14 trap the escape of cryogen, resulting in complications such as perforations and tears.

15 Accordingly, there is a need in the art for an improved method and system for
16 delivering ablative agents to a tissue surface, for providing a consistent, controlled,
17 and uniform ablation of the target tissue, and for minimizing the adverse side effects
18 of introducing ablative agents into a patient.

19 20 **Summary of the Invention**

21 The present invention is directed toward a device to perform ablation of
22 endometrial tissue, comprising a catheter having a shaft through which an ablative
23 agent can travel, a first positioning element attached to said catheter shaft at a first
24 position, wherein said first positioning element is configured to center said catheter in
25 a center of a cervix, and a second positioning element attached to said catheter shaft at
26 a second position, wherein the shaft comprises a plurality of ports through which said
27 ablative agent can be released out of said shaft and wherein said ports are located
28 between said first position and second position.

29 Optionally, the first positioning element is conical. The first positioning
30 element comprises an insulated membrane which can be configured to prevent an
31 escape of thermal energy through the cervix. The second positioning element is disc
32 shaped. The second positioning element has a dimension which can be used to
33 determine a uterine cavity size. The second positioning element has a dimension
34 which can be used to calculate an amount of thermal energy needed to ablate the

1 endometrial tissue. The device also includes at least one temperature sensor, which
2 can be used to control delivery of the ablative agent, such as steam.

3 Optionally, the second positioning element is separated from endometrial
4 tissue to be ablated by a distance of greater than 0.1 mm. The first positioning
5 element is a covered wire mesh. The first positioning element comprises a circular
6 body with a diameter between 0.1 mm and 10cm. The second positioning element is
7 oval and wherein said oval has a long axis between 0.1 mm and 10 cm and a short
8 axis between 0.1 mm and 5 cm.

9 In another embodiment, the present invention is directed toward a device to
10 perform ablation of endometrial tissue, comprising a catheter having a hollow shaft
11 through which steam can be delivered, a first positioning element attached to said
12 catheter shaft at a first position, wherein said first positioning element is conical and
13 configured to center said catheter in a center of a cervix, a second positioning element
14 attached to said catheter shaft at a second position, wherein the second positioning
15 element is disc shaped, a plurality of ports integrally formed in said catheter shaft,
16 wherein steam can be released out of said ports and directed toward endometrial
17 tissue and wherein said ports are located between said first position and second
18 position; and at least one temperature sensor.

19 Optionally, the second positioning element has a dimension, which can be
20 used to determine a uterine cavity size. The second positioning element has a
21 dimension, which can be used to calculate an amount of thermal energy needed to
22 ablate the endometrial tissue. The temperature sensors are used to control delivery of
23 said ablative agent. The first positioning element comprises wire mesh. The second
24 positioning element has a disc shape that is oval and wherein said oval has a long axis
25 between 0.1mm and 10 cm and a short axis between 0.1 mm and 5 cm.

26 A device to perform ablation of tissue in a hollow organ, comprising a catheter
27 having a shaft through which an ablative agent can travel; a first positioning element
28 attached to said catheter shaft at a first position, wherein said first positioning element
29 is configured to position said catheter at a predefined distance from the tissue to be
30 ablated; and wherein the shaft comprises one or more port through which said ablative
31 agent can be released out of said shaft.

32 Optionally, the device further comprises a second positioning element attached
33 to said catheter shaft at a position different from said first positioning element. The
34 first positioning element is at least one of a conical shape, disc shape, or a free form

1 shape conformed to the shape of the hollow organ. The second positioning element
2 has predefined dimensions and wherein said predefined dimensions are used to
3 determine the dimensions of the hollow organ to be ablated. The first positioning
4 element comprises an insulated membrane. The insulated membrane is configured to
5 prevent an escape of thermal energy. The second positioning element is at least one
6 of a conical shape, disc shape, or a free form shape conformed to the shape of the
7 hollow organ. The second positioning element has predefined dimensions and
8 wherein said predefined dimensions are used to determine the dimensions of the
9 hollow organ to be ablated. The second positioning element has a predefined
10 dimension and wherein said predefined dimension is used to calculate an amount of
11 thermal energy needed to ablate the tissue. The device further comprises at least one
12 temperature sensor. The temperature sensor is used to control delivery of said
13 ablative agent. The ablative agent is steam. The first positioning element is a covered
14 wire mesh. The first positioning element comprises a circular body with a diameter
15 between 0.01 mm and 10cm. The first positioning element is oval and wherein said
16 oval has a long axis between 0.01 mm and 10 cm and a short axis between 0.01 mm
17 and 9 cm.

18 In another embodiment, the present invention is directed to a device to
19 perform ablation of tissue in a hollow organ, comprising a catheter having a hollow
20 shaft through which steam can be delivered; a first positioning element attached to
21 said catheter shaft at a first position, wherein said first positioning element is
22 configured to position said catheter at a predefined distance from the surface of the
23 hollow organ; a second positioning element attached to said catheter shaft at a second
24 position, wherein the second positioning element is shaped to position said catheter at
25 a predefined distance from the surface of the hollow organ; a plurality of ports
26 integrally formed in said catheter shaft, wherein steam can be released out of said
27 ports and directed toward tissue to be ablated and wherein said ports are located
28 between said first position and second position; and at least one temperature sensor.

29 Optionally, the first positioning element has a predefined dimension and
30 wherein said dimension is used to determine the size of the hollow organ. The second
31 positioning element has a predefined dimension and wherein said dimension is used to
32 calculate an amount of thermal energy needed to ablate the tissue. The temperature
33 sensor is used to control delivery of said ablative agent. The first positioning element
34 comprises wire mesh. The second positioning element has a disc shape that is oval

1 and wherein said oval has a long axis between 0.01mm and 10 cm and a short axis
2 between 0.01 mm and 9 cm.

3 In another embodiment, the present invention is directed to a device to
4 perform ablation of the gastrointestinal tissue, comprising a catheter having a shaft
5 through which an ablative agent can travel; a first positioning element attached to said
6 catheter shaft at a first position, wherein said first positioning element is configured to
7 position the catheter at a fixed distance from the gastrointestinal tissue to be ablated,
8 and wherein said first positioning element is separated from an ablation region by a
9 distance of between 0 mm and 5 cm, and an input port at a second position and in
10 fluid communication with said catheter shaft in order to receive said ablative agent
11 wherein the shaft comprises one or more ports through which said ablative agent can
12 be released out of said shaft.

13 Optionally, the first positioning element is at least one of an inflatable balloon,
14 wire mesh disc or cone. By introducing said ablative agent into said ablation region,
15 the device creates an gastrointestinal pressure equal to or less than 5 atm. The
16 ablative agent has a temperature between -100 degrees Celsius and 200 degrees
17 Celsius. The catheter further comprises a temperature sensor. The catheter further
18 comprises a pressure sensor. The first positioning element is configured to abut a
19 gastroesophageal junction when placed in a gastric cardia. The ports are located
20 between said first position and second position. The diameter of the positioning
21 element is between 0.01 mm and 100 mm. The ablative agent is steam. The first
22 positioning element comprises a circular body with a diameter between 0.01 mm and
23 10cm.

24 In another embodiment, the present invention is directed toward a device to
25 perform ablation of esophageal tissue, comprising a catheter having a hollow shaft
26 through which steam can be transported; a first positioning element attached to said
27 catheter shaft at a first position, wherein said first positioning element is configured to
28 abut a gastroesophageal junction when placed in a gastric cardia; and an input port at
29 a second position and in fluid communication with said catheter shaft in order to
30 receive said steam wherein the shaft comprises a plurality of ports through which said
31 steam can be released out of said shaft and wherein said ports are located between
32 said first position and second position. The device further comprises a temperature
33 sensor wherein said temperature sensor is used to control the release of said steam.
34 The first positioning element comprises at least one of a wire mesh disc, a wire mesh

1 cone, or an inflatable balloon. The first positioning element is separated from an
2 ablation region by a distance of between 0 mm and 1 cm. The diameter of the first
3 positioning element is between 1 mm and 100 mm.

4 In another embodiment, the present invention is directed to a device to
5 perform ablation of gastrointestinal tissue, comprising a catheter having a hollow
6 shaft through which steam can be transported; a first positioning element attached to
7 said catheter shaft at a first position, wherein said first positioning element is
8 configured to abut the gastrointestinal tissue; and an input port at a second position
9 and in fluid communication with said catheter shaft in order to receive said steam
10 wherein the shaft comprises one or more ports through which said steam can be
11 released out of said shaft onto the gastrointestinal tissue.

12 Optionally, the device further comprises a temperature sensor wherein said
13 temperature sensor is used to control the release of said steam. The first positioning
14 element comprises at least one of a wire mesh disc and a wire mesh cone. The
15 diameter of the first positioning element is 0.1mm to 50mm. The device is used to
16 perform non-circumferential ablation.

17 In another embodiment, the present invention is directed to a device to
18 perform ablation of endometrial tissue, comprising a catheter having a shaft through
19 which an ablative agent can travel; a first positioning element attached to said catheter
20 shaft at a first position, wherein said first positioning element is configured to center
21 said catheter in a center of a cervix; and a shaft comprises a plurality of ports through
22 which said ablative agent can be released out of said shaft.

23 Optionally, the device further comprises a second positioning element attached
24 to said catheter shaft at a second position. The first positioning element is conical.
25 The first positioning element comprises an insulated membrane. The insulated
26 membrane is configured to prevent an escape of thermal energy through the cervix.
27 The second positioning element is disc shaped. The second positioning element has a
28 predefined dimension and wherein said dimension is used to determine a uterine
29 cavity size. The second positioning element has a predefined dimension and wherein
30 said dimension is used to calculate an amount of thermal energy needed to ablate the
31 endometrial tissue. The device further comprises at least one temperature sensor
32 wherein said temperature sensor is used to control delivery of said ablative agent.
33 The ablative agent is steam. The first positioning element is a covered wire mesh.
34 The first positioning element comprises a circular body with a diameter between 0.01

1 mm and 10cm. The second positioning element is oval and wherein said oval has a long axis between 0.01 mm and 10 cm and a short axis between 0.01 mm and 5 cm.

3 In another embodiment, the present invention is directed toward a device to perform ablation of endometrial tissue, comprising a catheter having a hollow shaft through which steam can be delivered; a first positioning element attached to said catheter shaft at a first position, wherein said first positioning element is conical and configured to center said catheter in a center of a cervix; a second positioning element attached to said catheter shaft at a second position, wherein the second positioning element is elliptical shaped; a plurality of ports integrally formed in said catheter shaft, wherein steam can be released out of said ports and directed toward endometrial tissue and wherein said ports are located between said first position and second position; and at least one temperature sensor.

13 Optionally, the second positioning element has a predefined dimension and wherein said dimension is used to determine a uterine cavity size. The second positioning element has a diameter and wherein said diameter is used to calculate an amount of thermal energy needed to ablate the endometrial tissue. The temperature sensors are used to control delivery of said ablative agent. The first positioning element comprises wire mesh. The second positioning element has a disc shape that is oval and wherein said oval has a long axis between 0.01mm and 10 cm and a short axis between 0.01 mm and 5 cm.

21 Optionally, the second positioning element can use one or more sources of infrared, electromagnetic, acoustic or radiofrequency energy to measure the dimensions of the hollow cavity. The energy is emitted from the sensor and is reflected back to the detector in the sensor. The reflected data is used to determine the dimension of the hollow cavity.

26 **Brief Description of the Drawings**

27 The present invention is described by way of embodiments illustrated in the accompanying drawings wherein:

29 FIG.1. illustrates an ablation device, in accordance with an embodiment of the present invention;

31 FIG.2a illustrates a longitudinal section of an ablation device with ports distributed thereon;

33 FIG.2b illustrates a cross section of a port on the ablation device, in accordance with an embodiment of the present invention;

1 FIG.2c illustrates a cross section of a port on the ablation device, in
2 accordance with another embodiment of the present invention;

3 FIG.2d illustrates a catheter of the ablation device, in accordance with an
4 embodiment of the present invention;

5 FIG.3a. illustrates the ablation device placed in an upper gastrointestinal tract
6 with Barrett esophagus to selectively ablate the Barrett tissue, in accordance with an
7 embodiment of the present invention;

8 FIG.3b. illustrates the ablation device placed in an upper gastrointestinal tract
9 with Barrett esophagus to selectively ablate the Barrett tissue, in accordance with
10 another embodiment of the present invention;

11 FIG.3c is a flowchart illustrating the basic procedural steps for using the
12 ablation device, in accordance with an embodiment of the present invention;

13 FIG.4a illustrates the ablation device placed in a colon to ablate a flat colon
14 polyp, in accordance with an embodiment of the present invention;

15 FIG.4b illustrates the ablation device placed in a colon to ablate a flat colon
16 polyp, in accordance with another embodiment of the present invention;

17 FIG.5a illustrates the ablation device with a coaxial catheter design, in
18 accordance with an embodiment of the present invention;

19 FIG.5b illustrates a partially deployed positioning device, in accordance with
20 an embodiment of the present invention;

21 FIG.5c illustrates a completely deployed positioning device, in accordance
22 with an embodiment of the present invention;

23 FIG.5d illustrates the ablation device with a conical positioning element, in
24 accordance with an embodiment of the present invention;

25 FIG.5e illustrates the ablation device with a disc shaped positioning element,
26 in accordance with an embodiment of the present invention;

27 FIG.6 illustrates an upper gastrointestinal tract with a bleeding vascular lesion
28 being treated by the ablation device, in accordance with an embodiment of the present
29 invention;

30 FIG.7 illustrates endometrial ablation being performed in a female uterus by
31 using the ablation device, in accordance with an embodiment of the present invention;

32 FIG.8 illustrates sinus ablation being performed in a nasal passage by using
33 the ablation device, in accordance with an embodiment of the present invention;

1 FIG.9 illustrates bronchial and bullous ablation being performed in a
2 pulmonary system by using the ablation device, in accordance with an embodiment of
3 the present invention;

4 FIG.10 illustrates prostate ablation being performed on an enlarged prostate
5 in a male urinary system by using the device, in accordance with an embodiment of
6 the present invention;

7 FIG.11 illustrates fibroid ablation being performed in a female uterus by using
8 the ablation device, in accordance with an embodiment of the present invention;

9 FIG.12 illustrates a vapor delivery system using an RF heater for supplying
10 vapor to the ablation device, in accordance with an embodiment of the present
11 invention; and

12 FIG.13 illustrates a vapor delivery system using a resistive heater for
13 supplying vapor to the ablation device, in accordance with an embodiment of the
14 present invention.

15

16 **Detailed Description of the Invention**

17 The present invention provides an ablation device comprising a catheter with
18 one or more centering or positioning attachments at one or more ends of the catheter
19 to affix the catheter and its infusion port at a fixed distance from the ablative tissue
20 which is not affected by the movements of the organ. The arrangement of one or more
21 spray ports allows for uniform spray of the ablative agent producing a uniform
22 ablation of large area such as Barrett esophagus. The flow of ablative agent is
23 controlled by the microprocessor and depends upon one or more of the length or area
24 of tissue to be ablated, type and depth of tissue to be ablated and distance of the
25 infusion port from the tissue to be ablated.

26 “Treat,” “treatment,” and variations thereof refer to any reduction in the
27 extent, frequency, or severity of one or more symptoms or signs associated with a
28 condition.

29 “Duration” and variations thereof refer to the time course of a prescribed
30 treatment, from initiation to conclusion, whether the treatment is concluded because
31 the condition is resolved or the treatment is suspended for any reason. Over the
32 duration of treatment, a plurality of treatment periods may be prescribed during which
33 one or more prescribed stimuli are administered to the subject.

1 “Period” refers to the time over which a “dose” of stimulation is administered
2 to a subject as part of the prescribe treatment plan.

3 The term “and/or” means one or all of the listed elements or a combination of
4 any two or more of the listed elements.

5 The terms “comprises” and variations thereof do not have a limiting meaning
6 where these terms appear in the description and claims.

7 Unless otherwise specified, “a,” “an,” “the,” “one or more,” and “at least one”
8 are used interchangeably and mean one or more than one.

9 For any method disclosed herein that includes discrete steps, the steps may be
10 conducted in any feasible order. And, as appropriate, any combination of two or more
11 steps may be conducted simultaneously.

12 Also herein, the recitations of numerical ranges by endpoints include all
13 numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5,
14 etc.). Unless otherwise indicated, all numbers expressing quantities of components,
15 molecular weights, and so forth used in the specification and claims are to be
16 understood as being modified in all instances by the term “about.” Accordingly,
17 unless otherwise indicated to the contrary, the numerical parameters set forth in the
18 specification and claims are approximations that may vary depending upon the
19 desired properties sought to be obtained by the present invention. At the very least,
20 and not as an attempt to limit the doctrine of equivalents to the scope of the claims,
21 each numerical parameter should at least be construed in light of the number of
22 reported significant digits and by applying ordinary rounding techniques.

23 Notwithstanding that the numerical ranges and parameters setting forth the
24 broad scope of the invention are approximations, the numerical values set forth in the
25 specific examples are reported as precisely as possible. All numerical values,
26 however, inherently contain a range necessarily resulting from the standard deviation
27 found in their respective testing measurements.

28 Ablative agents such as steam, heated gas or cryogens such as but not limited
29 to liquid nitrogen are inexpensive and readily available, and are directed via the
30 infusion port onto the tissue, held at a fixed and consistent distance, targeted for
31 ablation. This allows for uniform distribution of the ablative agent on the targeted
32 tissue. The flow of the ablative agent is controlled by a microprocessor according to a
33 predetermined method based on the characteristic of the tissue to be ablated, required
34 depth of ablation, and distance of the port from the tissue. The microprocessor may

1 use temperature, pressure or other sensing data to control the flow of the ablative
2 agent. In addition, one or more suction ports are provided to suction the ablation agent
3 from the vicinity of the targeted tissue. The targeted segment can be treated by a
4 continuous infusion of the ablative agent or via cycles of infusion and removal of the
5 ablative agent as determined and controlled by the microprocessor.

6 It should be appreciated that the devices and embodiments described herein
7 are implemented in concert with a controller that comprises a microprocessor
8 executing control instructions. The controller can be in the form of any computing
9 device, including desktop, laptop, and mobile device, and can communicate control
10 signals to the ablation devices in wired or wireless form.

11 The following disclosure is provided in order to enable a person having
12 ordinary skill in the art to practice the invention. Exemplary embodiments are
13 provided only for illustrative purposes and various modifications will be readily
14 apparent to persons skilled in the art. The general principles defined herein may be
15 applied to other embodiments and applications without departing from the spirit and
16 scope of the invention. Also, the terminology and phraseology used is for the purpose
17 of describing exemplary embodiments and should not be considered limiting. Thus,
18 the present invention is to be accorded the widest scope encompassing numerous
19 alternatives, modifications and equivalents consistent with the principles and features
20 disclosed. For purpose of clarity, details relating to technical material that is known in
21 the technical fields related to the invention have not been described in detail so as not
22 to unnecessarily obscure the present invention. The present invention will now be
23 discussed in context of embodiments as illustrated by the accompanying drawings.

24 Figure 1 illustrates an ablation device, in accordance with an embodiment of
25 the present invention. The ablation device comprises a catheter 10 having a distal
26 centering or positioning attachment which is an inflatable balloon 11. The catheter 10
27 is made of or covered with an insulated material to prevent the escape of ablative
28 energy from the catheter body. The ablation device comprises one or more infusion
29 ports 12 for the infusion of ablative agent and one or more suction ports 13 for the
30 removal of ablative agent. In one embodiment, the infusion port 12 and suction port
31 13 are the same. Ablative agent is stored in a reservoir 14 connected to the catheter
32 10. Delivery of the ablative agent is controlled by a microprocessor 15 and initiation
33 of the treatment is controlled by a treating physician using an input device, such as a
34 foot-paddle 16. In other embodiments, the input device could be a voice recognition

1 system (that is responsive to commands such as “start”, “more”, “less”, etc.), a mouse,
2 a switch, footpad, or any other input device known to persons of ordinary skill in the
3 art. In one embodiment, microprocessor 15 translates signals from the input device,
4 such as pressure being placed on the foot-paddle or vocal commands to provide
5 “more” or “less” ablative agent, into control signals that determine whether more or
6 less ablative agent is dispensed. Optional sensor 17 monitors changes in an ablative
7 tissue or its vicinity to guide flow of ablative agent. Optional infrared,
8 electromagnetic, acoustic or radiofrequency energy emitter and sensor 18 measures
9 the dimensions of the hollow organ.

10

11 In one embodiment, the inflatable balloon has a diameter of between 1mm and 10cm.
12 In one embodiment, the inflatable balloon is separated from the ports by a distance of
13 1mm to 10cm. In one embodiment, the size of the port openings are between 1 μ m
14 and 1 cm. It should be appreciated that the inflatable balloon is used to fix the device
15 and therefore is configured to not contact the ablated area. The inflatable balloon can
16 be any shape that contacts the hollow organ at 3 or more points. One of ordinary skill
17 in the art that, using triangulation, one can calculate the distance of the catheter from
18 the lesion. Alternatively the infrared, electromagnetic, acoustic or radiofrequency
19 energy emitter and sensor 18 can measure the dimensions of the hollow organ. The
20 infrared, electromagnetic, acoustic or radiofrequency energy is emitted from the
21 emitter 18 and is reflected back from the tissue to the detector in the emitter 18. The
22 reflected data can be used to determine the dimension of the hollow cavity. It should
23 be appreciated that the emitter and sensor 18 can be incorporated into a single
24 transceiver that is capable of both emitting energy and detecting the reflected energy.

25 Figure 2a illustrates a longitudinal section of the ablation device, depicting a
26 distribution of infusion ports. Figure 2b illustrates a cross section of a distribution of
27 infusion ports on the ablation device, in accordance with an embodiment of the
28 present invention. The longitudinal and cross sectional view of the catheter 10 as
29 illustrated in Figures 2a and 2b respectively, show one arrangement of the infusion
30 ports 12 to produce a uniform distribution of ablative agent 21 in order to provide a
31 circumferential area of ablation in a hollow organ 20. Figure 2c illustrates a cross
32 section of a distribution of infusion ports on the ablation device, in accordance with
33 another embodiment of the present invention. The arrangement of the infusion ports

12 as illustrated in Figure 2c produce a focal distribution of ablative agent 21 and a focal area of ablation in a hollow organ 20.

For all embodiments described herein, it should be appreciated that the size of the port, number of ports, and distance between the ports will be determined by the volume of ablative agent needed, pressure that the hollow organ can withstand, size of the hollow organ as measured by the distance of the surface from the port, length of the tissue to be ablated (which is roughly the surface area to be ablated), characteristics of the tissue to be ablated and depth of ablation needed. In one embodiment, there is at least one port opening that has a diameter between 1 μm and 1 cm. In another embodiment, there is two or more port openings that have a diameter between 1 μm and 1 cm and that are equally spaced around the perimeter of the device.

Figure 2d illustrates another embodiment of the ablation device. The vapor ablation catheter comprises an insulated catheter 21 with one or more positioning attachments 22 of known length 23. The vapor ablation catheter has one or more vapor infusion ports 25. The length 24 of the vapor ablation catheter 21 with infusion ports 25 is determined by the length or area of the tissue to be ablated. Vapor 29 is delivered through the vapor infusion ports 25. The catheter 21 is preferably positioned in the center of the positioning attachment 22, and the infusion ports 25 are arranged circumferentially for circumferential ablation and delivery of vapor. In another embodiment, the catheter 21 can be positioned toward the periphery of the positioning attachment 22 and the infusion ports 25 can be arranged non-circumferentially, preferably linearly on one side for focal ablation and delivery of vapor. The positioning attachment 23 is one of an inflatable balloon, a wire mesh disc with or without an insulated membrane covering the disc, a cone shaped attachment, a ring shaped attachment or a freeform attachment designed to fit the desired hollow body organ or hollow body passage, as further described below. Optional infrared, electromagnetic, acoustic or radiofrequency energy emitter and sensor 28 are incorporated to measures the dimensions of the hollow organ.

The vapor ablation catheter may also comprise an optional coaxial sheet 27 to restrain the positioning attachment 22 in a manner comparable to a coronary metal stent. In one embodiment, the disc is made of memory metal or memory material with a compressed linear form and a non-compressed form in the shape of the positioning attachment. Alternatively, the channel of an endoscope may perform the

1 function of restraining the positioning attachment 22 by, for example, acting as a
2 constraining sheath. Optional sensor 26 is deployed on the catheter to measure
3 changes associated with vapor delivery or ablation. The sensor is one of temperature,
4 pressure, photo or chemical sensor.

5 [001] Optional, one or more, infrared, electromagnetic, acoustic or
6 radiofrequency energy emitter and sensor 28 can measure the dimensions of the
7 hollow organ. The infrared, electromagnetic, acoustic or radiofrequency energy is
8 emitted from the emitter 18 and is reflected back from the tissue to the detector in the
9 emitter 18. The reflected data can be used to determine the dimension of the hollow
10 cavity. The measurement is performed at one or multiple points to get an accurate
11 estimate of the dimension of the hollow organ. The data can also be used to create a
12 topographic representation of the hollow organ.

13 Figure 3a illustrates the ablation device placed in an upper gastrointestinal
14 tract with Barrett esophagus to selectively ablate the Barrett tissue, in accordance with
15 an embodiment of the present invention. The upper gastrointestinal tract comprises
16 Barrett esophagus 31, gastric cardia 32, gastroesophageal junction 33 and displaced
17 squamo-columnar junction 34. The area between gastroesophageal junction 33 and
18 displaced squamo-columnar junction 34 is Barrett esophagus 31, which is targeted for
19 ablation. Distal to the cardia 32 is the stomach 35 and proximal to the cardia 32 is the
20 esophagus 36. The ablation device is passed into the esophagus 36 and the positioning
21 device 11 is placed in the gastric cardia 32 abutting the gastroesophageal junction 33.
22 This affixes the ablation catheter 10 and its ports 12 in the center of the esophagus 36
23 and allows for uniform delivery of the ablative agent 21 to the Barrett esophagus 31.

24 In one embodiment, the positioning device is first affixed to an anatomical structure,
25 not being subjected to ablation, before ablation occurs. Where the patient is
26 undergoing circumferential ablation or first time ablation, the positioning attachment
27 is preferably placed in the gastric cardia, abutting the gastroesophageal junction.
28 Where the patient is undergoing a focal ablation of any residual disease, it is
29 preferable to use the catheter system shown in Figure 4b, as discussed below. In one
30 embodiment, the positioning attachment must be separated from the ablation region
31 by a distance of greater than 0 mm, preferably 1 mm and ideally 1 cm. In one
32 embodiment, the size of the positioning device is in the range of 10 to 100 mm,
33 preferably 20-40 mm, although one of ordinary skill in the art would appreciate that
34 the precise dimensions are dependent on the size of the patient's esophagus.

1 The delivery of ablative agent 21 through the infusion port 12 is controlled by
2 the microprocessor 15 coupled with the ablation device. The delivery of ablative
3 agent is guided by predetermined programmatic instructions, depending on the tissue
4 to be ablated and the depth of ablation required. In one embodiment, the target
5 procedural temperature will need to be between -100 degrees Celsius and 200 degrees
6 Celsius, preferably between 50 degrees Celsius and 75 degrees Celsius, as further
7 shown in the dosimetry table below. In one embodiment, esophageal pressure
8 should not to exceed 5 atm, and is preferably below 0.5atm. In one embodiment, the
9 target procedural temperature is achieved in less than 1 minute, preferably in less than
10 5 seconds, and is capable of being maintained for up to 10 minutes, preferably 1 to 10
11 seconds, and then cooled to body temperature. One of ordinary skill in the art would
12 appreciate that the treatment can be repeated until the desired ablation effect is
13 achieved.

14 Optional sensor 17 monitors intraluminal parameters such as temperature and
15 pressure and can increase or decrease the flow of ablative agent 21 through the
16 infusion port 12 to obtain adequate heating or cooling, resulting in adequate ablation.
17 The sensor 17 monitors intraluminal parameters such as temperature and pressure and
18 can increase or decrease the removal of ablative agent 21 through the optional suction
19 port 13 to obtain adequate heating or cooling resulting in adequate ablation of Barrett
20 esophagus 31. Figure 3b illustrates the ablation device placed in an upper
21 gastrointestinal tract with Barrett esophagus to selectively ablate the Barrett tissue, in
22 accordance with another embodiment of the present invention. As illustrated in FIG.
23 3b, the positioning device 11 is a wire mesh disc. In one embodiment, the positioning
24 attachment must be separated from the ablation region by a distance of greater than 0
25 mm, preferably 1 mm and ideally 1 cm. In one embodiment, the positioning
26 attachment is removably affixed to the cardia or EG junction (for the distal
27 attachment) or in the esophagus by a distance of greater than 0.1 mm, preferably
28 around 1 cm, above the proximal most extent of the Barrett tissue (for the proximal
29 attachment).

30 FIG. 3b is another embodiment of the Barrett ablation device where the
31 positioning element 11 is a wire mesh disc. The wire mesh may have optional
32 insulated membrane to prevent the escape of the ablative agent. In the current
33 embodiment, two wire mesh discs are used to center the ablation catheter in the
34 esophagus. The distance between the two discs is determined by the length of the

1 tissue to ablated which, in this case, would be the length of the Barrett esophagus.
2 Optional infrared, electromagnetic, acoustic or radiofrequency energy emitter and
3 sensor 18 are incorporated to measures the diameter of the esophagus.

4 FIG. 3c is a flowchart illustrating the basic procedural steps for using the
5 ablation device, in accordance with an embodiment of the present invention. At step
6 302, a catheter of the ablation device is inserted into a hollow organ which is to be
7 ablated. For example, in order to perform ablation in a Barrett esophagus of a patient
8 the catheter is inserted into the Barrett esophagus via the esophagus of the patient.

9 At step 304, a positioning element of the ablation device is deployed. In an
10 embodiment, where the positioning element is a balloon, the balloon is inflated in
11 order to position the ablation device at a known fixed distance from the tissue to be
12 ablated. The diameter of the hollow organ may either be predetermined by using
13 radiological tests such as barium X-rays or computer tomography (CT) scan, or by
14 using pressure volume cycle, i.e by determining volume needed to raise pressure to a
15 fixed level (say 1atm) in a fixed volume balloon. In another embodiment, where the
16 positioning device is disc shaped, circumferential rings are provided in order to
17 visually communicate to an operating physician the diameter of the hollow organ. In
18 various embodiments of the present invention, the positioning device enables
19 centering of the catheter of the ablation device in a non-cylindrical body cavity, and
20 the volume of the cavity is measured by the length of catheter or a uterine sound.

21 Optional, one or more, infrared, electromagnetic, acoustic or radiofrequency
22 energy emitter and sensor can be used to measure the dimensions of the hollow organ.
23 The infrared, electromagnetic, acoustic or radiofrequency energy is emitted from the
24 emitter and is reflected back from the tissue to a detector in the emitter. The reflected
25 data can be used to determine the dimension of the hollow cavity. The measurement
26 can be performed at one or multiple points to get an accurate estimate of the
27 dimension of the hollow organ. The data from multiple points can also be used to
28 create a topographic representation of the hollow organ or to calculate the volume of
29 the hollow organ.

30 In one embodiment, the positioning attachment must be separated from the
31 ports by a distance of 0 mm or greater, preferably greater than 0.1 mm, and more
32 preferably 1 cm. The size of the positioning device depends on the hollow organ
33 being ablated and ranges from 1 mm to 10 cm. In one embodiment, the diameter of
34 the positioning element is between 0.01 mm and 100 mm. In one embodiment, the

1 first positioning element comprises a circular body with a diameter between 0.01 mm
2 and 10 cm.

3 At step 306, the organ is ablated by automated delivery of an ablative agent
4 such as steam via infusion ports provided on the catheter. The delivery of the ablative
5 agent through the infusion ports is controlled by a microprocessor coupled with the
6 ablation device. The delivery of ablative agent is guided by predetermined
7 programmatic instructions depending on the tissue to be ablated and the depth of
8 ablation required. In an embodiment of the present invention where the ablative agent
9 is steam, the dose of the ablative agent is determined by conducting dosimetry study
10 to determine the dose to ablate endometrial tissue. The variable that enables
11 determination of total dose of ablative agent is the volume (or mass) of the tissue to be
12 treated which is calculated by using the length of the catheter and diameter of the
13 organ (for cylindrical organs). The determined dose of ablative agent is then
14 delivered using micro-processor controlled steam generator.

15 In one embodiment, the dose is provided by first determining what the
16 disorder being treated is and what the desired tissue effect is, and then finding the
17 corresponding temperature, as shown in the tables below.

18

Temp	Tissue Effect
37-40	No significant tissue effect
41-44	Reversible cell damage in few hours
45-49	Irreversible cell damage at shorter intervals
50-69	Irreversible cell damage –ablation necrosis at shorter intervals
70	Threshold temp for tissue shrinkage, H-bond breakage
70-99	Coagulation and Hemostasis
100-200	Desiccation and Carbonization of tissue
> 200	Charring of tissue glucose

19

<u>Disorder</u>	<u>Max. Temp</u>
<u>ENT / Pulmonary</u>	
Nasal Polyp	60-80 C
Turbinectomy	70-85 C
Bullous Disease	70-85 C

Lung Reduction	70-85 C
<u>Genitourinary</u>	
Uterine Menorrhagia	80-90 C
Endometriosis	80-90 C
Uterine Fibroids	90-100 C
Benign Prostatic Hypertrophy	90-100 C
<u>Gastroenterology</u>	
Barrett Esophagus	60-75 C
Esophageal Dysplasia	60-80 C
Vascular GI Disorders	55-75 C
Flat Polyps	60-80 C

1

2 In addition, the depth of ablation desired determines the holding time at the
3 maximum temperature. For superficial ablation (Barrett), the holding time at the
4 maximum temperature is very short (flash burn) and does not allow for heat to
5 transfer to the deeper layers. This will prevent damage to deeper normal tissue and
6 hence prevention patient discomfort and complication. For deeper tissue ablation, the
7 holding time at the maximum temperature will be longer, thereby allowing the heat to
8 percolate deeper.

9 Figure 4a illustrates the ablation device placed in a colon to ablate a flat colon
10 polyp, in accordance with an embodiment of the present invention. The ablation
11 catheter 10 is passed through a colonoscope 40. The positioning device 11 is placed
12 proximal to a flat colonic polyp 41 which is to be ablated, in the normal colon 42. The
13 positioning device 11 is one of an inflatable balloon, a wire mesh disc with or without
14 an insulated membrane covering the disc, a cone shaped attachment, a ring shaped
15 attachment or a freeform attachment designed to fit the colonic lumen. The
16 positioning device 11 has the catheter 10 located toward the periphery of the
17 positioning device 11 placing it closer to the polyp 41 targeted for non-circumferential
18 ablation. Hence, the positioning device 11 fixes the catheter to the colon 42 at a
19 predetermined distance from the polyp 41 for uniform and focused delivery of the
20 ablative agent 21. The delivery of ablative agent 21 through the infusion port 12 is

1 controlled by the microprocessor 15 attached to the ablation device and depends on
2 tissue and the depth of ablation required. The delivery of ablative agent 21 is guided
3 by predetermined programmatic instructions depending on the tissue to be ablated and
4 the area and depth of ablation required. The ablation device allows for focal ablation
5 of diseased polyp mucosa without damaging the normal colonic mucosa located away
6 from the catheter ports.

7 In one embodiment, the positioning attachment must be separated from the
8 ablation region by a distance of greater than 0.1 mm, ideally more than 5 mm. In one
9 embodiment, the positioning element is proximal to the colon polyp. For this
10 application, the embodiment shown in Figure 4b would be preferred.

11 Figure 4b illustrates the ablation device placed in a colon to ablate a flat colon
12 polyp, in accordance with another embodiment of the present invention. As illustrated
13 in Figure 4b, the positioning device is a conical attachment at the tip of the catheter.
14 The conical attachment has a known length 'l' and diameter 'd' that is used to
15 calculate the amount of thermal energy needed to ablate the flat colon polyp. In one
16 embodiment, the positioning attachment must be separated from the ablation region
17 by a distance of greater than 0.1 mm, preferably 1 mm and more preferably 1 cm. In
18 one embodiment, the length 'l' is greater than 0.1 mm, preferably between 5 and 10
19 mm. In one embodiment, diameter 'd' depends on the size of the polyp and can be
20 between 1 mm and 10 cm, preferably 1 to 5 cm. This embodiment can also be used to
21 ablate residual neoplastic tissue at the edges after endoscopic snare resection of a
22 large sessile colon polyp.

23 Figure 5a illustrates the ablation device with a coaxial catheter design, in
24 accordance with an embodiment of the present invention. The coaxial design has a
25 handle 52a, an infusion port 53a, an inner sheath 54a and an outer sheath 55a. The
26 outer sheath 55a is used to constrain the positioning device 56a in the closed position
27 and encompasses ports 57a. Figure 5b shows a partially deployed positioning device
28 56b, with the ports 57b still within the outer sheath 55b. The positioning device 56b
29 is partially deployed by pushing the catheter 54b out of sheath 55b.

30 Figure 5c shows a completely deployed positioning device 56c. The infusion
31 ports 57c are out of the sheath 55c. The length 'l' of the catheter 54c that contains the
32 infusion port 57c and the diameter 'd' of the positioning element 56c are
33 predetermined / known and are used to calculate the amount of thermal energy
34 needed. Figure 5d illustrates a conical design of the positioning element. The

1 positioning element 56d is conical with a known length 'l' and diameter 'd' that is
2 used to calculate the amount of thermal energy needed for ablation. Figure 5e
3 illustrates a disc shaped design of the positioning element 56e comprising
4 circumferential rings 59e. The circumferential rings 59e are provided at a fixed
5 predetermined distance and are used to estimate the diameter of a hollow organ or
6 hollow passage in a patient's body.

7 Figure 6 illustrates an upper gastrointestinal tract with a bleeding vascular
8 lesion being treated by the ablation device, in accordance with an embodiment of the
9 present invention. The vascular lesion is a visible vessel 61 in the base of an ulcer 62.
10 The ablation catheter 63 is passed through the channel of an endoscope 64. The conical
11 positioning element 65 is placed over the visible vessel 61. The conical positioning
12 element 65 has a known length 'l' and diameter 'd', which are used to calculate the
13 amount of thermal energy needed for coagulation of the visible vessel to achieve
14 hemostasis. The conical positioning element has an optional insulated membrane that
15 prevents escape of thermal energy or vapor away from the disease site.

16 In one embodiment, the positioning attachment must be separated from the
17 ablation region by a distance of greater than 0.1 mm, preferably 1 mm and more
18 preferably 1 cm. In one embodiment, the length 'l' is greater than 0.1 mm, preferably
19 between 5 and 10 mm. In one embodiment, diameter 'd' depends on the size of the
20 lesion and can be between 1 mm and 10 cm, preferably 1 to 5 cm.

21 Figure 7 illustrates endometrial ablation being performed in a female uterus by
22 using the ablation device, in accordance with an embodiment of the present invention.
23 A cross-section of the female genital tract comprising a vagina 70, a cervix 71, a
24 uterus 72, an endometrium 73, fallopian tubes 74, ovaries 75 and the fundus of the
25 uterus 76 is illustrated. A catheter 77 of the ablation device is inserted into the uterus
26 72 through the cervix 71. In an embodiment, the catheter 77 has two positioning
27 elements, a conical positioning element 78 and a disc shaped positioning element 79.
28 The positioning element 78 is conical with an insulated membrane covering the
29 conical positioning element 78. The conical element 78 positions the catheter 77 in
30 the center of the cervix 71 and the insulated membrane prevents the escape of thermal
31 energy or ablative agent through the cervix 71. The second disc shaped positioning
32 element 79 is deployed close to the fundus of the uterus 76 positioning the catheter 77
33 in the middle of the cavity. An ablative agent 778 is passed through infusion ports 777
34 for uniform delivery of the ablative agent 778 into the uterine cavity. Predetermined

length “l” of the ablative segment of the catheter and diameter ‘d’ of the positioning element 79 allows for estimation of the cavity size and is used to calculate the amount of thermal energy needed to ablate the endometrial lining. Optional temperature sensors 7 deployed close to the endometrial surface are used to control the delivery of the ablative agent 778. Optional topographic mapping using multiple infrared, electromagnetic, acoustic or radiofrequency energy emitter and sensor can be used to define cavity size and shape in patients with irregular or deformed uterine cavity due to conditions such as fibroids.

In an embodiment, the ablative agent is steam which contracts on cooling. Steam turns to water which has a lower volume as compared to a cryogen that will expand or a hot fluid used in hydrothermal ablation whose volume stays constant. With both cryogens and hot fluids, increasing energy delivery is associated with increasing volume of the ablative agent which, in turn, requires mechanisms for removing the agent, otherwise the medical provider will run into complications. However, steam, on cooling, turn into water which occupies significantly less volume; therefore, increasing energy delivery is not associated with an increase in volume of the residual ablative agent, thereby eliminating the need for continued removal. This further decreases the risk of leakage of the thermal energy via the fallopian tubes 74 or the cervix 71, thus reducing any risk of thermal injury to adjacent healthy tissue.

In one embodiment, the positioning attachment must be separated from the ablation region by a distance of greater than 0.1 mm, preferably 1 mm and more preferably 1 cm. In another embodiment, the positioning attachment can be in the ablated region as long as it does not cover a significant surface area. For endometrial ablation, 100% of the tissue does not need to be ablated to achieve the desired therapeutic effect.

In one embodiment, the preferred distal positioning attachment is an uncovered wire mesh that is positioned proximate to the mid body region. In one embodiment, the preferred proximal positioning device is a covered wire mesh that is pulled into the cervix, centers the device, and occludes the cervix. One or more such positioning devices may be helpful to compensate for the anatomical variations in the uterus. The proximal positioning device is preferably oval, with a long axis being between 0.1mm and 10cm (preferably 1cm to 5cm) and a short axis between 0.1mm and 5cm (preferably 0.5cm to 1cm). The distal positioning device is preferably circular with a diameter between 0.1 mm and 10cm, preferably 1cm to 5cm.

1 Figure 8 illustrates sinus ablation being performed in a nasal passage by using
2 the ablation device, in accordance with an embodiment of the present invention. A
3 cross-section of the nasal passage and sinuses comprising nares 81, nasal passages 82,
4 frontal sinus 83, ethmoid sinus 84, and diseased sinus epithelium 85 is illustrated. The
5 catheter 86 is inserted into the frontal sinus 83 or the ethmoid sinus 84 through the
6 nares 81 and nasal passages 82.

7 In an embodiment, the catheter 86 has two positioning elements, a conical
8 positioning element 87 and a disc shaped positioning element 88. The positioning
9 element 87 is conical and has an insulated membrane covering. The conical element
10 87 positions the catheter 86 in the center of the sinus opening 80 and the insulated
11 membrane prevents the escape of thermal energy or ablative agent through the
12 opening. The second disc shaped positioning element 88 is deployed in the frontal
13 sinus cavity 83 or ethmoid sinus cavity 84, positioning the catheter 86 in the middle
14 of either sinus cavity. The ablative agent 8 is passed through the infusion port 89 for
15 uniform delivery of the ablative agent 8 into the sinus cavity. The predetermined
16 length 'l' of the ablative segment of the catheter and diameter 'd' of the positioning
17 element 88 allows for estimation of the sinus cavity size and is used to calculate the
18 amount of thermal energy needed to ablate the diseased sinus epithelium 85. Optional
19 temperature sensors 888 are deployed close to the diseased sinus epithelium 85 to
20 control the delivery of the ablative agent 8. In an embodiment, the ablative agent 8 is
21 steam which contracts on cooling. This further decreases the risk of leakage of the
22 thermal energy thus reducing any risk of thermal injury to adjacent healthy tissue. In
23 one embodiment, the dimensional ranges of the positioning elements are similar to
24 those in the endometrial application, with preferred maximum ranges being half
25 thereof. Optional topographic mapping using multiple infrared, electromagnetic,
26 acoustic or radiofrequency energy emitter and sensor can be used to define cavity size
27 and shape in patients with irregular or deformed nasal cavity due to conditions such as
28 nasal polyps.

29 Figure 9 illustrates bronchial and bullous ablation being performed in a
30 pulmonary system by using the ablation device, in accordance with an embodiment of
31 the present invention. A cross-section of the pulmonary system comprising bronchus
32 91, normal alveolus 92, bullous lesion 93, and a bronchial neoplasm 94 is illustrated.

33 In one embodiment, the catheter 96 is inserted through the channel of a
34 bronchoscope 95 into the bronchus 91 and advanced into a bullous lesion 93. The

1 catheter 96 has two positioning elements, a conical positioning element 97 and a disc
2 shaped positioning element 98. The positioning element 97 is conical having an
3 insulated membrane covering. The conical element 97 positions the catheter 96 in the
4 center of the bronchus 91 and the insulated membrane prevents the escape of thermal
5 energy or ablative agent through the opening into the normal bronchus. The second
6 disc shaped positioning element 98 is deployed in the bullous cavity 93 positioning
7 the catheter 96 in the middle of the bullous cavity 93. An ablative agent 9 is passed
8 through the infusion port 99 for uniform delivery into the sinus cavity. Predetermined
9 length "l" of the ablative segment of the catheter 96 and diameter 'd' of the
10 positioning element 98 allow for estimation of the bullous cavity size and is used to
11 calculate the amount of thermal energy needed to ablate the diseased bullous cavity
12 93. Optionally the size of the cavity can be calculated from radiological evaluation
13 using a chest CAT scan or MRI. Optional temperature sensors are deployed close to
14 the surface of the bullous cavity 93 to control the delivery of the ablative agent 9. In
15 an embodiment, the ablative agent is steam which contracts on cooling. This further
16 decreases the risk of leakage of the thermal energy into the normal bronchus thus
17 reducing any risk of thermal injury to adjacent normal tissue.

18 In one embodiment, the positioning attachment must be separated from the
19 ablation region by a distance of greater than 0.1 mm, preferably 1 mm and more
20 preferably 1 cm. In another embodiment, the positioning attachment can be in the
21 ablated region as long as it does not cover a significant surface area.

22 In one embodiment, there are preferably two positioning attachments. In
23 another embodiment, the endoscope is used as one fixation point with one positioning
24 element. The positioning device is between 0.1mm and 5cm (preferably 1 mm to 2
25 cm). The distal positioning device is preferably circular with a diameter between 0.1
26 mm and 10cm, preferably 1cm to 5cm.

27 In another embodiment for the ablation of a bronchial neoplasm 94, the
28 catheter 96 is inserted through the channel of a bronchoscope 95 into the bronchus 91
29 and advanced across the bronchial neoplasm 94. The positioning element 98 is disc
30 shaped having an insulated membrane covering. The positioning element 98 positions
31 the catheter in the center of the bronchus 91 and the insulated membrane prevents the
32 escape of thermal energy or ablative agent through the opening into the normal
33 bronchus. The ablative agent 9 is passed through the infusion port 99 in a non-
34 circumferential pattern for uniform delivery of the ablative agent to the bronchial

1 neoplasm 94. The predetermined length "l" of the ablative segment of the catheter and
2 diameter 'd' of the positioning element 98 are used to calculate the amount of thermal
3 energy needed to ablate the bronchial neoplasm 94.

4 Figure 10 illustrates prostate ablation being performed on an enlarged
5 prostate in a male urinary system by using the device, in accordance with an
6 embodiment of the present invention. A cross-section of a male genitourinary tract
7 having an enlarged prostate 101, bladder 102, and urethra 103 is illustrated. The
8 urethra 103 is compressed by the enlarged prostate 101. The ablation catheter 105 is
9 passed through the cystoscope 104 positioned in the urethra 103 distal to the
10 obstruction. The positioning elements 106 are deployed to center the catheter in the
11 urethra 103 and insulated needles 107 are passed to pierce the prostate 101. The vapor
12 ablative agent 108 is passed through the insulated needles 107 thus causing ablation
13 of the diseased prostatic tissue resulting in shrinkage of the prostate.

14 In one embodiment, the positioning attachment must be separated from the
15 ablation region by a distance of greater than 0.1 mm, preferably 1 mm to 5 mm and no
16 more than 2 cm. In another embodiment, the positioning attachment can be deployed
17 in the bladder and pulled back into the urethral opening /neck of the bladder thus
18 fixing the catheter. In one embodiment, the positioning device is between 0.1mm and
19 10 cm.

20 Figure 11 illustrates fibroid ablation being performed in a female uterus by
21 using the ablation device, in accordance with an embodiment of the present invention.
22 A cross-section of a female genitourinary tract comprising a uterine fibroid 111,
23 uterus 112, and cervix 113 is illustrated. The ablation catheter 115 is passed through
24 the hysteroscope 114 positioned in the uterus distal to the fibroid 111. The ablation
25 catheter 115 has a puncturing tip 120 that helps puncture into the fibroid 111. The
26 positioning elements 116 are deployed to center the catheter in the fibroid and
27 insulated needles 117 are passed to pierce the fibroid tissue 111. The vapor ablative
28 agent 118 is passed through the needles 117 thus causing ablation of the uterine
29 fibroid 111 resulting in shrinkage of the fibroid.

30 Figure 12 illustrates a vapor delivery system using an RF heater for supplying
31 vapor to the ablation device, in accordance with an embodiment of the present
32 invention. In an embodiment, the vapor is used as an ablative agent in conjunction
33 with the ablation device described in the present invention. RF heater 64 is located
34 proximate a pressure vessel 42 containing a liquid 44. RF heater 64 heats vessel 42, in

1 turn heating the liquid 44. The liquid 44 heats up and begins to evaporate causing an
2 increase in pressure inside the vessel 42. The pressure inside vessel 42 can be kept
3 fairly constant by providing a thermal switch 46 that controls resistive heater 64.
4 Once, the temperature of the liquid 44 reaches a predetermined temperature, the
5 thermal switch 46 shuts off RF heater 64. The vapor created in pressure vessel 42 may
6 be released via a control valve 50. As the vapor exits vessel 42, a pressure drop is
7 created in the vessel resulting in a reduction in temperature. The reduction of
8 temperature is measured by thermal switch 46, and RF heater 64 is turned back on to
9 heat liquid 44. In one embodiment, the target temperature of vessel 42 may be set to
10 approximately 108°C, providing a continuous supply of vapor. As the vapor is
11 released, it undergoes a pressure drop, which reduces the temperature of the vapor to a
12 range of approximately 90-100° C. As liquid 44 in vessel 42 evaporates and the vapor
13 exits vessel 42, the amount of liquid 44 slowly diminishes. The vessel 42 is optionally
14 connected to reservoir 43 containing liquid 44 via a pump 49 which can be turned on
15 by the controller 24 upon sensing a fall in pressure or temperature in vessel 42
16 delivering additional liquid 44 to the vessel 42.

17 Vapor delivery catheter 16 is connected to vessel 42 via a fluid connector 56.
18 When control valve 50 is open, vessel 42 is in fluid communication with delivery
19 catheter 16 via connector 56. Control switch 60 may serve to turn vapor delivery on
20 and off via actuator 48. For example, control switch 60 may physically open and
21 close the valve 50, via actuator 48, to control delivery of vapor stream from the vessel
22 42. Switch 60 may be configured to control other attributes of the vapor such as
23 direction, flow, pressure, volume, spray diameter, or other parameters.

24 Instead of, or in addition to, physically controlling attributes of the vapor,
25 switch 60 may electrically communicate with a controller 24. Controller 24 controls
26 the RF heater 64, which in turn controls attributes of the vapor, in response to
27 actuation of switch 60 by the operator. In addition, controller 24 may control valves
28 temperature or pressure regulators associated with catheter 16 or vessel 42. A flow
29 meter 52 may be used to measure the flow, pressure, or volume of vapor delivery via
30 the catheter 16. The controller 24 controls the temperature and pressure in the vessel
31 42 and the time, rate, flow, volume of vapor flow through the control valve 50. These
32 parameters are set by the operator 11. The pressure created in vessel 42, using the
33 target temperature of 108° c., may be in the order of 25 pounds per square inch (psi)
34 (1.72 bars).

1 Figure 13 illustrates a vapor delivery system using a resistive heater for
2 supplying vapor to the ablation device, in accordance with an embodiment of the
3 present invention. In an embodiment, the generated vapor is used as an ablative agent
4 in conjunction with the ablation device described in the present invention. Resistive
5 heater 40 is located proximate a pressure vessel 42. Vessel 42 contains a liquid 44.
6 Resistive heater 40 heats vessel 42, in turn heating liquid 44. Accordingly, liquid 44
7 heats and begins to evaporate. As liquid 44 begins to evaporate, the vapor inside
8 vessel 42 causes an increase in pressure in the vessel. The pressure in vessel 42 can be
9 kept fairly constant by providing a thermal switch 46 that controls resistive heater 40.
10 When the temperature of liquid 44 reaches a predetermined temperature, thermal
11 switch 46 shuts off resistive heater 40. The vapor created in pressure vessel 42 may be
12 released via a control valve 50. As the vapor exits vessel 42, vessel 42 experiences a
13 pressure drop. The pressure drop of vessel 42 results in a reduction of temperature.
14 The reduction of temperature is measured by thermal switch 46, and resistive heater
15 40 is turned back on to heat liquid 44. In one embodiment, the target temperature of
16 vessel 42 may be set to approximately 108°C, providing a continuous supply of vapor.
17 As the vapor is released, it undergoes a pressure drop, which reduces the temperature
18 of the vapor to a range of approximately 90-100° C. As liquid 44 in vessel 42
19 evaporates and the vapor exits vessel 42, the amount of liquid 44 slowly diminishes.
20 The vessel 42 is connected to another vessel 43 containing liquid 44 via a pump 49
21 which can be turned on by the controller 24 upon sensing a fall in pressure or
22 temperature in vessel 44 delivering additional liquid 44 to the vessel 42.

23 Vapor delivery catheter 16 is connected to vessel 42 via a fluid connector 56.
24 When control valve 50 is open, vessel 42 is in fluid communication with delivery
25 catheter 16 via connector 56. Control switch 60 may serve to turn vapor delivery on
26 and off via actuator 48. For example, control switch 60 may physically open and close
27 the valve 50, via actuator 48, to control delivery of vapor stream from the vessel 42.
28 Switch 60 may be configured to control other attributes of the vapor such as direction,
29 flow, pressure, volume, spray diameter, or other parameters. Instead of, or in addition
30 to, physically controlling attributes of the vapor, switch 60 may electrically
31 communicate with a controller 24. Controller 24 controls the resistive heater 40,
32 which in turn controls attributes of the vapor, in response to actuation of switch 60 by
33 the operator. In addition, controller 24 may control valves temperature or pressure
34 regulators associated with catheter 16 or vessel 42. A flow meter 52 may be used to

1 measure the flow, pressure, or volume of vapor delivery via the catheter 16. The
2 controller 24 controls the temperature and pressure in the vessel 42 as well as time,
3 rate, flow, volume of vapor flow through the control valve 50. These parameters are
4 set by the operator 11. The pressure created in vessel 42, using the target temperature
5 of 108°C, may be on the order of 25 pounds per square inch (psi) (1.72 bars).

6 The device and method of the present invention can be used to cause
7 controlled focal or circumferential ablation of targeted tissue to varying depth in a
8 manner in which complete healing with re-epithelialization can occur. The dose and
9 manner of treatment can be adjusted based on the type of tissue and the depth of
10 ablation needed. The ablation device can be used not only for the treatment of Barrett
11 esophagus and esophageal dysplasia, flat colon polyps, gastrointestinal bleeding
12 lesions, endometrial ablation, pulmonary ablation, but also for the treatment of any
13 mucosal, submucosal or circumferential lesion, such as inflammatory lesions, tumors,
14 polyps and vascular lesions. The ablation device can also be used for the treatment of
15 focal or circumferential mucosal or submucosal lesion of any hollow organ or hollow
16 body passage in the body. The hollow organ can be one of gastrointestinal tract,
17 pancreaticobiliary tract, genitourinary tract, respiratory tract or a vascular structure
18 such as blood vessels. The ablation device can be placed endoscopically,
19 radiologically, surgically or under direct visualization. In various embodiments,
20 wireless endoscopes or single fiber endoscopes can be incorporated as a part of the
21 device.

22 While the exemplary embodiments of the present invention are described and
23 illustrated herein, it will be appreciated that they are merely illustrative. It will be
24 understood by those skilled in the art that various changes in form and detail may be
25 made therein without departing from or offending the spirit and scope of the
26 invention.

27
28
29

1 **CLAIMS**


2 We claim:

- 3 1. A device to perform ablation of tissue in a hollow organ, comprising
 - 4 a. a catheter having a shaft through which an ablative agent can travel;
 - 5 b. a first positioning element attached to said catheter shaft at a first
6 position, wherein said first positioning element is configured to
7 position said catheter at a predefined distance from the tissue to be
8 ablated; and
 - 9 c. wherein the shaft comprises one or more port through which said
10 ablative agent can be released out of said shaft.
- 11 2. The device of claim 1 further comprising a second positioning element
12 attached to said catheter shaft at a position different from said first positioning
13 element.
- 14 3. The device of claim 1 wherein the first positioning element is at least one of a
15 conical shape, disc shape, or a free form shape conformed to the shape of the
16 hollow organ.
- 17 4. The device of claim 3 wherein the second positioning element has predefined
18 dimensions and wherein said predefined dimensions are used to determine the
19 dimensions of the hollow organ to be ablated.
- 20 5. The device of claim 1 wherein the first positioning element comprises an
21 insulated membrane wherein said insulated membrane is configured to prevent
22 an escape of thermal energy.
- 23 6. The device of claim 1 further comprising at least one of acoustic,
24 electromagnetic, infrared or radiofrequency energy sensor wherein said sensor
25 is used to measure the dimension of the hollow organ
- 26 7. The device of claim 2 wherein said second positioning element is at least one
27 of a conical shape, disc shape, or a free form shape conformed to the shape of
28 the hollow organ.
- 29 8. The device of claim 7 wherein the second positioning element has predefined
30 dimensions and wherein said predefined dimensions are used to determine the
31 dimensions of the hollow organ to be ablated.
- 32 9. The device of claim 8 wherein the second positioning element has a
33 predefined dimension and wherein said predefined dimension is used to
34 calculate an amount of thermal energy needed to ablate the tissue.
- 35 10. The device of claim 1 further comprising at least one temperature sensor.
- 36 11. The device of claim 10 wherein said temperature sensor is used to control
37 delivery of said ablative agent.

12. The device of claim 1 wherein said ablative agent is steam.
13. The device of claim 1 wherein said first positioning element is a covered wire mesh.
14. The device of claim 1 wherein said first positioning element comprises a circular body with a diameter between 0.01 mm and 10cm.
15. The device of claim 1 wherein said first positioning element is oval and wherein said oval has a long axis between 0.01 mm and 10 cm and a short axis between 0.01 mm and 9 cm.
16. A device to perform ablation of tissue in a hollow organ, comprising
 - a. a catheter having a hollow shaft through which steam can be delivered;
 - b. a first positioning element attached to said catheter shaft at a first position, wherein said first positioning element is configured to position said catheter at a predefined distance from the surface of the hollow organ;
 - c. a second positioning element attached to said catheter shaft at a second position, wherein the second positioning element is shaped to position said catheter at a predefined distance from the surface of the hollow organ;
 - d. a plurality of ports integrally formed in said catheter shaft, wherein steam can be released out of said ports and directed toward tissue to be ablated and wherein said ports are located between said first position and second position; and
 - e. at least one temperature sensor.
17. The device of claim 16 wherein said first positioning element has a predefined dimension and wherein said dimension is used to determine the size of the hollow organ.
18. The device of claim 16 wherein the second positioning element has a predefined dimension and wherein said dimension is used to calculate an amount of thermal energy needed to ablate the tissue.
19. The device of claim 16 wherein said at least one temperature sensor is used to control delivery of said ablative agent.
20. The device of claim 1 wherein said second positioning element has a disc shape that is oval and wherein said oval has a long axis between 0.01mm and 10 cm and a short axis between 0.01 mm and 9 cm.
21. A device to perform ablation of endometrial tissue, comprising
 - a. a catheter having a shaft through which an ablative agent can travel;
 - b. a first positioning element attached to said catheter shaft at a first position, wherein said first positioning element is configured to center said catheter in a center of a cervix; and

- 1 c. a shaft comprises a plurality of ports through which said ablative agent
2 can be released out of said shaft.
3
- 4 22. The device of claim 22 further comprising a second positioning element
5 attached to said catheter shaft at a second position.
6
- 7 23. A device to perform ablation of the gastrointestinal tissue, comprising
8 a. a catheter having a shaft through which an ablative agent can travel;
9 b. a first positioning element attached to said catheter shaft at a first
10 position wherein said first positioning element is configured to position
11 the catheter at a fixed distance from the gastrointestinal tissue to be
12 ablated, and
13 c. an input port at a second position and in fluid communication with said
14 catheter shaft in order to receive said ablative agent wherein the shaft
15 comprises one or more ports through which said ablative agent can be
16 released out of said shaft.
17
- 18 24. The device of claim 23 further comprising a second positioning element
19 attached to said catheter shaft, wherein said ports are located between said first
20 position and second position.
21

1/17

**FIG. 1**

2/17

FIG. 2B

FIG. 2C




FIG. 2A

3/17





FIG. 2D

4/17

**FIG. 3A**

5/17




FIG. 3B

6/17





FIG. 3C

7/17



8/17




FIG. 4B

FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D





FIG. 5E



10/17




FIG. 6




FIG. 7

12/17




FIG. 8

13/17




FIG. 9

14/17







FIG. 10

15/17







INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 09/59609

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61B 18/04 (2010.01)

USPC - 607/105

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
USPC- 607/105Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
USPC- 604/264, 93.01, 48, 19, 919, 113; 606/27; 607/96, 104, 105, 113

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWest (USPT,PGPB,EPAB,JPAB), Google, Google Patents

Search Terms Used: organ, tissue, uterus, uterine, endometrial, gastrointestinal, GI, alimentary, cavity, ablation, necrosis, cauterization, catheter, shaft, tube, pipe, positioner, locator, spacer, conical, disc, disk, free-form, distance, spacing, gap, offset, wire, metallic, mesh,

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6,960,203 B2 (Xiao et al.) 01 November 2005 (01.11.2005), col 1, ln 5-9, 56, 57, col 2, ln 56-63, col 3, ln 20-23, 28-31, 67 to col 4, ln 2, col 5, ln 4-10, 39-46, col 6, ln 6-11, 20-24, 27-30, 41-44, 50-52, col 7, ln 17-20, 38-40, fig 1, 2, 5-7, 14.	1-5, 10, 11, 14, 15, 21, 22
Y		6-9, 12, 13, 16-20
Y	US 3,938,502 A (Bom) 17 February 1976 (17.02.1976), col 1, ln 13-19, 61 to col 2, ln 2, 4-7.	6
Y	US 6,837,886 B2 (Collins et al.) 04 January 2005 (04.01.2005), Abstract, col 6, ln 6-14, fig 14, fig 22.	7-9, 20
Y	US 2002/0177846 A1 (Mulier et al.) 28 November 2002 (28.11.2002), para [0006], [0009].	12, 16-20
Y	US 6,112,123 A (Kelleher et al.) 29 August 2000 (29.08.2000), Abstract, col 1, ln 6-9, col 5, ln 66 to col 6, ln 2, col 8, ln 9-12, col 10, ln 66 to col 11, ln 7, col 12, ln 48-51, col 13, ln 50-59, fig 1A, 5B.	9, 18, 23, 24
Y	US 5,540,658 A (Evans et al.) 30 July 1996 (30.07.1996), Abstract, col 5, ln 47-52, col 6, ln 47-52.	13, 17
Y	US 6,238,389 B1 (Paddock et al.) 29 May 2001 (29.05.2001), col 1, ln 5-8, col 4, ln 28-36.	13
Y	US 5,954,714 A (Sadaat et al.) 21 September 1999 (21.09.1999), col 1, ln 5-7, col 6, ln 65 to col 7, ln 2.	20
Y	US 7,025,762 B2 (Johnston et al.) 11 April 2006 (11.04.2006), col 1, ln 15-19, col 8, ln 50-59.	23, 24

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

02 February 2010 (02.02.2010)

Date of mailing of the international search report

05 MAR 2010

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774